Intercept Shares Soar 20% After FDA Announces Breakthrough Therapy Designation For NASH Drug
January 30, 2015 at 10:46 AM EST
Intercept's OCA drug is designated a breakthrough therapy for treating a particular liver disease.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
